Trial | NCT03568877  Report issue

Title

Effect of Metabolaid® on AMPK Activation for Weight Loss
Anti-obesity Effects of Metabolaid® With AMPK-activating Capacity in Overweight Subjects: A Randomized Controlled Trial

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    46
The objective of this study was to establish a formulation, containing both Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) extracts (Metabolaid®) that had significant capacity to activate the AMPK-enzyme and to reduce triglyceride accumulation in the hypertrophied adipocyte model. Then, we assessed the efficacy of this combination in light-to-moderate-overweight subjects under risk of developing metabolic syndrome.
AMP-activated protein kinase (AMPK) has been postulated as a molecular target in the amelioration of obesity-related diseases, where most therapeutic approaches have failed. Plant-polyphenols have shown the capacity to ameliorate obesity-induced metabolic disturbances. A combination of polyphenols (LC-HS) derived from Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) (lemon verbena) (Metabolaid®) was assessed for triglyceride accumulation and AMPK activation in the hypertrophied adipocyte model 3T3-L1. A dietary supplement containing 500 mg of LC-HS was evaluated in a double blind, placebo-controlled and randomized trial in 56 overweight subjects for two months. Anthropometric and circulating biochemical parameters were determined.
Study Started
Mar 31
2015
Primary Completion
Jul 31
2015
Study Completion
Jul 31
2015
Last Update
Jun 27
2018

Dietary Supplement Metabolaid® [hibiscus sabdariffa, verbena]

500 mg per day, in fasting conditions.

Dietary Supplement Placebo

500 mg per day, in fasting conditions.

Placebo Control Placebo Comparator

2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks

Dietetic Supplement Group Experimental

2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks

Criteria 

Inclusion Criteria:

Participants with a body mass index (BMI) from 24 to 34 kg/m2

Exclusion Criteria:

total cholesterol lower than 200 mg/dL.
use of prescription medication for cholesterol or hypertension.
presence of any obesity-related pathology.
hormone replacement therapy.
consumption of antioxidant supplements/drugs.
alcohol addiction.
women who were pregnant or lactating.
No Results Posted